10x Genomics, Inc. reports results for the quarter ended June 30 - Earnings Summary

10x Genomics

06/08/2026 22:01

10x Genomics, Inc. TXG.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 28 cents.  The mean expectation of fifteen analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -36 cents to -16 cents per share.
Revenue fell 12.6% to $151.04 million from a year ago; analysts expected $146.79 million. 
10x Genomics, Inc.'s reported EPS for the quarter was a loss of 14 cents​.
The company reported a quarterly loss of $17.93 million.
10x Genomics, Inc. shares had risen by 23.8% this quarter and gained 191.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" 
Wall Street's median 12-month price target for 10x Genomics, Inc. is $40.00, about 18.7% below its last closing price of $47.46
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.24
-0.14
Beat
Mar. 31 2026 
-0.29
-0.10
Beat
Dec. 31 2025 
-0.21
-0.13
Beat
Sep. 30 2025 
-0.29
-0.22
Beat